{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:45:31Z","timestamp":1792154731084,"version":"4.4.0"},"reference-count":151,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["ZIA AA000360-04"],"award-info":[{"award-number":["ZIA AA000360-04"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.ejmech.2024.117205","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T20:15:57Z","timestamp":1735071357000},"page":"117205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["A review of kappa opioid receptor antagonists and their clinical trial landscape"],"prefix":"10.1016","volume":"287","author":[{"given":"Maloba M.M.","family":"Lobe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saroj","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishali M.","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0116-4619","authenticated-orcid":false,"given":"Malliga R.","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.117205_bib1","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1073\/pnas.70.7.1947","article-title":"Stereospecific binding of the potent narcotic analgesic (3H) etorphine to rat-brain homogenate","volume":"70","author":"Simon","year":"1973","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2024.117205_bib2","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1126\/science.179.4077.1011","article-title":"Opiate receptor: demonstration in nervous tissue","volume":"179","author":"Pert","year":"1973","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2024.117205_bib3","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1126\/science.1335167","article-title":"Cloning of a delta opioid receptor by functional expression","volume":"258","author":"Evans","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2024.117205_bib4","doi-asserted-by":"crossref","first-page":"12048","DOI":"10.1073\/pnas.89.24.12048","article-title":"The delta-opioid receptor: isolation of a CDNA by expression cloning and pharmacological characterization","volume":"89","author":"Kieffer","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2024.117205_bib5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0026-895X(25)13175-1","article-title":"Molecular cloning and functional expression of a mu-opioid receptor from rat brain","volume":"44","author":"Chen","year":"1993","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.117205_bib6","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0014-5793(93)80240-U","article-title":"Cloning and expression of a CDNA for the rat kappa-opioid receptor","volume":"329","author":"Minami","year":"1993","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejmech.2024.117205_bib7","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0031-6997(25)06958-3","article-title":"International union of pharmacology. XII. Classification of opioid receptors","volume":"48","author":"Dhawan","year":"1996","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejmech.2024.117205_bib8","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1146\/annurev.pharmtox.40.1.389","article-title":"Molecular mechanisms and regulation of opioid receptor signaling","volume":"40","author":"Law","year":"2000","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejmech.2024.117205_bib9","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.tins.2012.11.002","article-title":"Opioid receptors: distinct roles in mood disorders","volume":"36","author":"Lutz","year":"2013","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.ejmech.2024.117205_bib10","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/164_2016_116","article-title":"Insights into the role of opioid receptors in the GI tract: experimental evidence and therapeutic relevance","volume":"239","author":"Galligan","year":"2017","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.117205_bib11","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1177\/0963689718811060","article-title":"Historical review: opiate addiction and opioid receptors","volume":"28","author":"Wang","year":"2019","journal-title":"Cell Transplant."},{"key":"10.1016\/j.ejmech.2024.117205_bib12","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/0160-9327(82)90072-2","article-title":"Brain opiates","volume":"6","author":"Rossier","year":"1982","journal-title":"Endeavour"},{"key":"10.1016\/j.ejmech.2024.117205_bib13","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1126\/science.6120570","article-title":"Dynorphin is a specific endogenous ligand of the kappa opioid receptor","volume":"215","author":"Chavkin","year":"1982","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2024.117205_bib14","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0014-2999(82)90008-5","article-title":"Evidence that dynorphin-(1-13) acts as an agonist on opioid kappa-receptors","volume":"77","author":"Oka","year":"1982","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.117205_bib15","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1126\/science.6128790","article-title":"Comparison of the distribution of dynorphin systems and enkephalin systems in brain","volume":"218","author":"Watson","year":"1982","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2024.117205_bib16","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/164_2019_268","article-title":"The rise and fall of kappa-opioid receptors in drug Abuse research","volume":"258","author":"Banks","year":"2020","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.117205_bib17","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev-pharmtox-010919-023317","article-title":"Kappa opioid receptor antagonists as potential therapeutics for stress-related disorders","volume":"60","author":"Jacobson","year":"2020","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejmech.2024.117205_bib18","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3389\/fpsyt.2014.00170","article-title":"The kappa opioid receptor: from addiction to depression, and back","volume":"5","author":"Lalanne","year":"2014","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.ejmech.2024.117205_bib19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/bs.irn.2017.08.001","article-title":"Dynorphin\/kappa opioid receptor signaling in preclinical models of alcohol, drug, and food addiction","volume":"136","author":"Karkhanis","year":"2017","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.ejmech.2024.117205_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114785","article-title":"A systematic review on the kappa opioid receptor and its ligands: new directions for the treatment of pain, anxiety, depression, and drug Abuse","volume":"243","author":"Khan","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117205_bib21","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1038\/s41467-023-37041-7","article-title":"Molecular mechanism of biased signaling at the kappa opioid receptor","volume":"14","author":"El Daibani","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2024.117205_bib22","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/da.22500","article-title":"Kappa-opioid antagonists for psychiatric disorders: from bench to clinical trials","volume":"33","author":"Carlezon","year":"2016","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.ejmech.2024.117205_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fnsys.2022.963691","article-title":"Dynorphin\/kappa opioid receptor system regulation on amygdaloid circuitry: implications for neuropsychiatric disorders","volume":"16","author":"Limoges","year":"2022","journal-title":"Front. Syst. Neurosci."},{"key":"10.1016\/j.ejmech.2024.117205_bib24","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/S0140-6736(18)31948-2","article-title":"Depression","volume":"392","author":"Malhi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2024.117205_bib25","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"STAR\u2217D study team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR\u2217D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.ejmech.2024.117205_bib26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/2045125317737264","article-title":"The role of selective serotonin reuptake inhibitors in preventing relapse of major depressive disorder","volume":"8","author":"Clevenger","year":"2018","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1016\/j.ejmech.2024.117205_bib27","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/164_2020_432","article-title":"Kappa opioid receptors in the pathology and treatment of major depressive disorder","volume":"271","author":"Browne","year":"2022","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.117205_bib28","doi-asserted-by":"crossref","first-page":"5674","DOI":"10.1523\/JNEUROSCI.23-13-05674.2003","article-title":"Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses","volume":"23","author":"McLaughlin","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejmech.2024.117205_bib29","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1124\/jpet.102.046433","article-title":"Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats","volume":"305","author":"Mague","year":"2003","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2024.117205_bib30","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/sj.npp.1300872","article-title":"Social defeat stress-induced behavioral responses are mediated by the endogenous kappa opioid system","volume":"31","author":"McLaughlin","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejmech.2024.117205_bib31","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.brainres.2009.09.074","article-title":"Dynorphin, stress, and depression","volume":"1314","author":"Knoll","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.ejmech.2024.117205_bib32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.pnpbp.2015.01.001","article-title":"Kappa opioid receptor signaling in the brain: circuitry and implications for treatment","volume":"62","author":"Crowley","year":"2015","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.ejmech.2024.117205_bib33","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.biopsych.2005.09.018","article-title":"The mesolimbic dopamine reward circuit in depression","volume":"59","author":"Nestler","year":"2006","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.ejmech.2024.117205_bib34","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1073\/pnas.89.6.2046","article-title":"Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway","volume":"89","author":"Spanagel","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2024.117205_bib35","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1021\/jm301783x","article-title":"Development of \u03ba opioid receptor antagonists","volume":"56","author":"Carroll","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117205_bib36","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.brainres.2018.09.023","article-title":"Dynorphin\/kappa-opioid receptor control of dopamine dynamics: implications for negative affective states and psychiatric disorders","volume":"1713","author":"Tejeda","year":"2019","journal-title":"Brain Res."},{"key":"10.1016\/j.ejmech.2024.117205_bib37","first-page":"4","article-title":"Major depressive disorder and kappa opioid receptor antagonists","volume":"1","author":"Li","year":"2016","journal-title":"Transl. Perioper. Pain Med"},{"key":"10.1016\/j.ejmech.2024.117205_bib38","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1017\/S2045796021000275","article-title":"Regional and national burden of anxiety disorders from 1990 to 2019: results from the global burden of disease study 2019","volume":"30","author":"Yang","year":"2021","journal-title":"Epidemiol. Psychiatr. Sci."},{"key":"10.1016\/j.ejmech.2024.117205_bib39","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1017\/S003329171200147X","article-title":"Global prevalence of anxiety disorders: a systematic review and meta-regression","volume":"43","author":"Baxter","year":"2013","journal-title":"Psychol. Med."},{"key":"10.1016\/j.ejmech.2024.117205_bib40","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/aps.2015.32","article-title":"The role of the dynorphin\/\u03ba opioid receptor system in anxiety","volume":"36","author":"Hang","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2024.117205_bib41","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.biopsych.2011.03.017","article-title":"Kappa opioid receptor signaling in the basolateral amygdala regulates conditioned fear and anxiety in rats","volume":"70","author":"Knoll","year":"2011","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.ejmech.2024.117205_bib42","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1016\/j.celrep.2016.02.069","article-title":"Dynorphin controls the gain of an amygdalar anxiety circuit","volume":"14","author":"Crowley","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2024.117205_bib43","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pharmthera.2007.06.011","article-title":"Dynorphin and the pathophysiology of drug addiction","volume":"116","author":"Shippenberg","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2024.117205_bib44","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1126\/science.278.5335.45","article-title":"Addiction is a brain disease, and it matters","volume":"278","author":"Leshner","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2024.117205_bib45","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF00433012","article-title":"Drug reinstatement of heroin-reinforced responding in the rat","volume":"79","author":"de Wit","year":"1983","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejmech.2024.117205_bib46","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/BF00432175","article-title":"Reinstatement of cocaine-reinforced responding in the rat","volume":"75","author":"de Wit","year":"1981","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejmech.2024.117205_bib47","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00213-002-1224-x","article-title":"The reinstatement model of drug relapse: history, methodology and major findings","volume":"168","author":"Shaham","year":"2003","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejmech.2024.117205_bib48","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejphar.2005.09.030","article-title":"Neurobiology of relapse to heroin and cocaine seeking: an update and clinical implications","volume":"526","author":"Bossert","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.117205_bib49","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00213-008-1122-y","article-title":"Stress-induced reinstatement of cocaine seeking is mediated by the kappa opioid system","volume":"200","author":"Redila","year":"2008","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejmech.2024.117205_bib50","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/syn.890130408","article-title":"Molecular alterations in the neostriatum of human cocaine addicts","volume":"13","author":"Hurd","year":"1993","journal-title":"Synapse"},{"key":"10.1016\/j.ejmech.2024.117205_bib51","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41386-019-0398-4","article-title":"Kappa-opioid receptors, dynorphin, and cocaine addiction: a positron emission tomography study","volume":"44","author":"Martinez","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejmech.2024.117205_bib52","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.psych.59.103006.093548","article-title":"Addiction and the brain antireward system","volume":"59","author":"Koob","year":"2008","journal-title":"Annu. Rev. Psychol."},{"key":"10.1016\/j.ejmech.2024.117205_bib53","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00213-010-1825-8","article-title":"The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of Abuse","volume":"210","author":"Wee","year":"2010","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejmech.2024.117205_bib54","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s00213-005-0167-4","article-title":"Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats","volume":"183","author":"Beardsley","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejmech.2024.117205_bib55","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejphar.2007.05.007","article-title":"Reinstatement of cocaine place-conditioning prevented by the peptide kappa-opioid receptor antagonist arodyn","volume":"569","author":"Carey","year":"2007","journal-title":"Eur. J. Pharmacol."},{"issue":"Suppl 1","key":"10.1016\/j.ejmech.2024.117205_bib56","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1360-0443.2006.01586.x","article-title":"The neurobiology of addiction: a neuroadaptational view relevant for diagnosis","volume":"101","author":"Koob","year":"2006","journal-title":"Addiction"},{"issue":"Suppl 1","key":"10.1016\/j.ejmech.2024.117205_bib57","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.neuropharm.2008.07.043","article-title":"Neurobiological substrates for the dark side of compulsivity in addiction","volume":"56","author":"Koob","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2024.117205_bib58","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1523\/JNEUROSCI.4458-07.2008","article-title":"The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system","volume":"28","author":"Land","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejmech.2024.117205_bib59","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1749-6632.1999.tb07876.x","article-title":"Stress, corticotropin-releasing factor, and drug addiction","volume":"897","author":"Koob","year":"1999","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejmech.2024.117205_bib60","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/s00213-005-0067-7","article-title":"A single injection of the kappa opioid antagonist norbinaltorphimine increases ethanol consumption in rats","volume":"182","author":"Mitchell","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejmech.2024.117205_bib61","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/sj.npp.1301438","article-title":"Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence","volume":"33","author":"Walker","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejmech.2024.117205_bib62","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/01.ALC.0000164361.62346.D6","article-title":"Decreased oral self-administration of alcohol in kappa-opioid receptor knock-out mice","volume":"29","author":"Kovacs","year":"2005","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.ejmech.2024.117205_bib63","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1369-1600.2010.00226.x","article-title":"Systemic \u03ba-opioid receptor antagonism by nor-binaltorphimine reduces dependence-induced excessive alcohol self-administration in rats","volume":"16","author":"Walker","year":"2011","journal-title":"Addiction Biol."},{"key":"10.1016\/j.ejmech.2024.117205_bib64","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00213-010-1844-5","article-title":"Endogenous kappa-opioid mediation of stress-induced potentiation of ethanol-conditioned place preference and self-administration","volume":"210","author":"Sperling","year":"2010","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejmech.2024.117205_bib65","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.pbb.2012.03.019","article-title":"Opioid regulation of anxiety-like behavior during acute ethanol withdrawal","volume":"102","author":"Valdez","year":"2012","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ejmech.2024.117205_bib66","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.biopsych.2019.05.012","article-title":"The role of dynorphin and the kappa opioid receptor in the symptomatology of schizophrenia: a review of the evidence","volume":"86","author":"Clark","year":"2019","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.ejmech.2024.117205_bib67","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11920-007-0041-7","article-title":"Dopamine hypothesis of schizophrenia: making sense of it all","volume":"9","author":"Toda","year":"2007","journal-title":"Curr. Psychiatr. Rep."},{"key":"10.1016\/j.ejmech.2024.117205_bib68","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.ejmech.2017.10.012","article-title":"Selective kappa opioid antagonists for treatment of addiction, are we there yet?","volume":"141","author":"Helal","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117205_bib69","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s00535-013-0753-x","article-title":"Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives","volume":"49","author":"Sobczak","year":"2014","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.ejmech.2024.117205_bib70","doi-asserted-by":"crossref","first-page":"11852","DOI":"10.1073\/pnas.1510117112","article-title":"NMR structure and dynamics of the agonist dynorphin peptide bound to the human kappa opioid receptor","volume":"112","author":"O'Connor","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2024.117205_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2020.146742","article-title":"Dynorphin and its role in alcohol use disorder","volume":"1735","author":"Karkhanis","year":"2020","journal-title":"Brain Res."},{"key":"10.1016\/j.ejmech.2024.117205_bib72","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/aps.2010.138","article-title":"The role of kappa-opioid receptor activation in mediating antinociception and addiction","volume":"31","author":"Wang","year":"2010","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2024.117205_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100503","article-title":"A novel luminescence-based \u03b2-arrestin recruitment assay for unmodified receptors","volume":"296","author":"Hauge Pedersen","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2024.117205_bib74","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nature10939","article-title":"Structure of the human \u03ba-opioid receptor in complex with JDTic","volume":"485","author":"Wu","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.117205_bib75","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.cell.2017.12.011","article-title":"Structure of the nanobody-stabilized active state of the kappa opioid receptor","volume":"172","author":"Che","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2024.117205_bib76","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/s41467-020-14889-7","article-title":"Nanobody-enabled monitoring of kappa opioid receptor states","volume":"11","author":"Che","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2024.117205_bib77","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.cell.2022.12.026","article-title":"Structures of the entire human opioid receptor family","volume":"186","author":"Wang","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2024.117205_bib78","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1021\/jm015521r","article-title":"Identification of the firsttrans -(3R ,4R)- dimethyl-4-(3-Hydroxyphenyl)Piperidine derivative to possess highly potent and selective opioid \u03ba receptor antagonist activity","volume":"44","author":"Thomas","year":"2001","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117205_bib79","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1146\/annurev-pharmtox-010716-104710","article-title":"Nanobodies to study G protein-coupled receptor structure and function","volume":"57","author":"Manglik","year":"2017","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejmech.2024.117205_bib80","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jphs.2015.11.008","article-title":"Nalfurafine hydrochloride, a selective \u03ba opioid receptor agonist, has No reinforcing effect on intravenous self-administration in rhesus monkeys","volume":"130","author":"Nakao","year":"2016","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2024.117205_bib81","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1017\/S0963180121000116","article-title":"The birth of naloxone: an intellectual history of an ambivalent opioid","volume":"30","author":"Kolbe","year":"2021","journal-title":"Camb. Q. Healthc. Ethics"},{"key":"10.1016\/j.ejmech.2024.117205_bib82","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1001\/jama.1971.03180260050019","article-title":"Naloxone treatment of opiate dependence","volume":"215","author":"Zaks","year":"1971","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2024.117205_bib83","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/archpsyc.1982.04290030047009","article-title":"Short-term naloxone administration in schizophrenic and manic patients. A world health organization collaborative study","volume":"39","author":"Pickar","year":"1982","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.ejmech.2024.117205_bib84","first-page":"83","article-title":"Opioid receptor Antagonists\u2217\u2217This review is dedicated to the memory of the late drs","volume":"vol. 35","author":"Schmidhammer","year":"1998"},{"key":"10.1016\/j.ejmech.2024.117205_bib85","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0306-4530(83)90043-4","article-title":"Effect of ACTH, epinephrine, beta-endorphin, naloxone, and of the combination of naloxone or beta-endorphin with ACTH or epinephrine on memory consolidation","volume":"8","author":"Izquierdo","year":"1983","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.ejmech.2024.117205_bib86","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1016\/j.celrep.2020.02.075","article-title":"Morphine and naloxone facilitate neural stem cells proliferation via a TET1-dependent and receptor-independent pathway","volume":"30","author":"Liang","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2024.117205_bib87","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1039\/D2QO00202G","article-title":"Concise total synthesis of opioids","volume":"9","author":"He","year":"2022","journal-title":"Org. Chem. Front."},{"key":"10.1016\/j.ejmech.2024.117205_bib88","volume":"vol. 2018","author":"Srivastava","year":"2018"},{"key":"10.1016\/j.ejmech.2024.117205_bib89","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/187152710790966704","article-title":"Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics","volume":"9","author":"Ray","year":"2010","journal-title":"CNS Neurol. Disord.: Drug Targets"},{"key":"10.1016\/j.ejmech.2024.117205_bib90","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/med.2610020302","article-title":"Naltrexone, opiate addiction, and endorphins","volume":"2","author":"Gold","year":"1982","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2024.117205_bib91","series-title":"Pharmacological Aspects of Drug Dependence","first-page":"563","article-title":"Long-term pharmacotherapy for opiate (primarily heroin) addiction: opioid antagonists and partial agonists","volume":"vol. 118","author":"Kreek","year":"1996"},{"key":"10.1016\/j.ejmech.2024.117205_bib92","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jad.2016.08.029","article-title":"Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants","volume":"208","author":"Mischoulon","year":"2017","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.ejmech.2024.117205_bib93","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1021\/jm00349a016","article-title":"Narcotic antagonistic potency of bivalent ligands which contain beta-naltrexamine. Evidence for bridging between proximal recognition sites","volume":"25","author":"Erez","year":"1982","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117205_bib94","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/0024-3205(85)90202-4","article-title":"TENA, a selective kappa opioid receptor antagonist","volume":"36","author":"Portoghese","year":"1985","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2024.117205_bib95","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1021\/jm00160a010","article-title":"Opioid agonist and antagonist bivalent ligands. The relationship between spacer length and selectivity at multiple opioid receptors","volume":"29","author":"Portoghese","year":"1986","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117205_bib96","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1021\/jm00155a048","article-title":"Investigation of the structural requirements for the kappa-selective opioid receptor antagonist, 6 Beta,6 beta\u2019-[ethylenebis(Oxyethyleneimino)]Bis[17-(cyclopropylmethyl)- 4,5 alpha-epoxymorphinan-3,14-diol] (TENA)","volume":"29","author":"Botros","year":"1986","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117205_bib97","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/0024-3205(87)90585-6","article-title":"Binaltorphimine and nor-binaltorphimine, potent and selective k-opioid receptor antagonists","volume":"40","author":"Portoghese","year":"1987","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2024.117205_bib98","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1021\/jm00108a008","article-title":"Role of the spacer in conferring kappa opioid receptor selectivity to bivalent ligands related to norbinaltorphimine","volume":"34","author":"Portoghese","year":"1991","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117205_bib99","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1021\/jm00385a002","article-title":"Bimorphinans as highly selective, potent kappa opioid receptor antagonists","volume":"30","author":"Portoghese","year":"1987","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117205_bib100","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/S0022-3565(25)11434-1","article-title":"Extremely long-lasting antagonistic actions of nor-binaltorphimine (nor-BNI) in the mouse tail-flick test","volume":"260","author":"Horan","year":"1992","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2024.117205_bib101","first-page":"30","article-title":"Nor-binaltorphimine: a potent and selective kappa-opioid receptor antagonist with long-lasting activity in vivo","volume":"316","author":"Endoh","year":"1992","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"10.1016\/j.ejmech.2024.117205_bib102","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0014-2999(93)90986-R","article-title":"Effects of nor-binaltorphimine on butorphanol dependence","volume":"239","author":"Jaw","year":"1993","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.117205_bib103","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejphar.2007.05.045","article-title":"Central kappa-opioid receptor-mediated antidepressant-like effects of nor-binaltorphimine: behavioral and BDNF MRNA expression studies","volume":"570","author":"Zhang","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.117205_bib104","unstructured":"Cran, J. Methods for the Chemical Synthesis of Pyrrole-Linked Bivalent Compounds, and Compositions Thereof. WO2016149608, September 22, 2016."},{"key":"10.1016\/j.ejmech.2024.117205_bib105","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/0165-6147(89)90267-8","article-title":"Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists","volume":"10","author":"Portoghese","year":"1989","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2024.117205_bib106","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1021\/ol0351854","article-title":"Efficient solid-phase synthesis of symmetric norbinaltorphimine derivatives","volume":"5","author":"Tanaka","year":"2003","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2024.117205_bib107","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/0028-3908(87)90112-2","article-title":"Buprenorphine has potent kappa opioid receptor antagonist activity","volume":"26","author":"Leander","year":"1987","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2024.117205_bib108","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF00442021","article-title":"Kappa antagonist properties of buprenorphine in non-tolerant and morphine-tolerant rats","volume":"98","author":"Negus","year":"1989","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejmech.2024.117205_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.dadr.2023.100133","article-title":"History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder","volume":"6","author":"Heidbreder","year":"2023","journal-title":"Drug and Alcohol Dependence Reports"},{"key":"10.1016\/j.ejmech.2024.117205_bib110","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2174\/1570159043359477","article-title":"Buprenorphine: a unique drug with complex pharmacology","volume":"2","author":"Lutfy","year":"2004","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.ejmech.2024.117205_bib111","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/00003495-197917020-00001","article-title":"Buprenorphine: a review of its pharmacological properties and therapeutic efficacy","volume":"17","author":"Heel","year":"1979","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.117205_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.101764","article-title":"Mechanistic origin of partial agonism of tetrahydrocannabinol for cannabinoid receptors","volume":"298","author":"Dutta","year":"2022","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2024.117205_bib113","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1749-6632.1982.tb39483.x","article-title":"Possible antidepressive effects of opioids: action of buprenorphine","volume":"398","author":"Emrich","year":"1982","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejmech.2024.117205_bib114","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/ijnp\/pyx077","article-title":"Effects of buprenorphine on responses to emotional stimuli in individuals with a range of mood symptomatology","volume":"21","author":"Bershad","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.ejmech.2024.117205_bib115","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1176\/appi.ajp.2015.15070921","article-title":"Opioid modulation with buprenorphine\/samidorphan as adjunctive treatment for inadequate response to antidepressants: a randomized double-blind placebo-controlled trial","volume":"173","author":"Fava","year":"2016","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.ejmech.2024.117205_bib116","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1038\/npp.2014.330","article-title":"Evaluation of opioid modulation in major depressive disorder","volume":"40","author":"Ehrich","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejmech.2024.117205_bib117","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/s41380-018-0284-1","article-title":"Opioid system modulation with buprenorphine\/samidorphan combination for major depressive disorder: two randomized controlled studies","volume":"25","author":"Fava","year":"2020","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.ejmech.2024.117205_bib118","doi-asserted-by":"crossref","first-page":"175","DOI":"10.9740\/mhc.2018.07.175","article-title":"Kappa opioid receptor antagonism: are opioids the answer for treatment resistant depression?","volume":"8","author":"Peckham","year":"2018","journal-title":"Ment. Health Clin."},{"key":"10.1016\/j.ejmech.2024.117205_bib119","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/2515408","article-title":"Buprenorphine alters inflammatory and oxidative stress molecular markers in arthritis","volume":"2017","author":"Hemshekhar","year":"2017","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.ejmech.2024.117205_bib120","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1002\/JLB.3CE0418-172R","article-title":"Buprenorphine: therapeutic potential beyond substance Abuse","volume":"104","author":"Velasquez","year":"2018","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.ejmech.2024.117205_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.tetlet.2022.154027","article-title":"Asymmetric total synthesis of buprenorphine and dihydroetorphine","volume":"104","author":"Tang","year":"2022","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.ejmech.2024.117205_bib122","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0014-2999(00)00208-9","article-title":"5\u2019-Guanidinonaltrindole, a highly selective and potent kappa-opioid receptor antagonist","volume":"396","author":"Jones","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.117205_bib123","doi-asserted-by":"crossref","first-page":"4911","DOI":"10.1021\/jm9805182","article-title":"Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors","volume":"41","author":"Jones","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117205_bib124","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1248\/bpb.b15-00090","article-title":"Methods for preclinical assessment of antipruritic agents and itch mechanisms independent of mast-cell histamine","volume":"38","author":"Kuraishi","year":"2015","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejmech.2024.117205_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2021.100097","article-title":"Itching-like behavior: a common effect of the kappa opioid receptor antagonist 5\u2032-guanidinonaltrindole and the biased kappa opioid receptor agonist 6\u2032-guanidinonaltrindole in mice","volume":"11","author":"Cowan","year":"2021","journal-title":"Medicine in Drug Discovery"},{"key":"10.1016\/j.ejmech.2024.117205_bib126","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejphar.2004.08.028","article-title":"Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist","volume":"501","author":"Carroll","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.117205_bib127","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1016\/j.bmc.2015.08.025","article-title":"Design, synthesis, and pharmacological evaluation of JDTic analogs to examine the significance of the 3- and 4-methyl substituents","volume":"23","author":"Carroll","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117205_bib128","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.ejmech.2014.12.016","article-title":"Novel fluoroalkyl derivatives of selective kappa opioid receptor antagonist JDTic: design, synthesis, pharmacology and molecular modeling studies","volume":"90","author":"Schmitt","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117205_bib129","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00213-010-1803-1","article-title":"Effect of the selective kappa-opioid receptor antagonist JDTic on nicotine antinociception, reward, and withdrawal in the mouse","volume":"210","author":"Jackson","year":"2010","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejmech.2024.117205_bib130","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1021\/jm030094y","article-title":"Identification of (3r)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-Hydroxyphenyl)- 3,4-dimethyl-1-Piperidinyl]Methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist","volume":"46","author":"Thomas","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117205_bib131","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1021\/jm980511k","article-title":"Identification of an opioid kappa receptor subtype-selective N-substituent for (+)-(3R,4R)-Dimethyl-4-(3-Hydroxyphenyl)Piperidine","volume":"41","author":"Thomas","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117205_bib132","doi-asserted-by":"crossref","first-page":"7367","DOI":"10.1021\/jm5008177","article-title":"Design, synthesis, and biological evaluation of (3R)-1,2,3,4-tetrahydro-7-hydroxy-N-[(1S)-1-[[(3R,4R)-4-(3-Hydroxyphenyl)-3,4-Dimethyl-1-Piperidinyl]Methyl]-2-Methylpropyl]-3-Isoquinolinecarboxamide (JDTic) analogues: in vitro pharmacology and ADME profile","volume":"57","author":"Kormos","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117205_bib133","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1021\/jo951403y","article-title":"Synthesis of trans-3,4-dimethyl-4-(3-Hydroxyphenyl)Piperidine opioid antagonists: application of the cis-thermal elimination of carbonates to alkaloid synthesis","volume":"61","author":"Werner","year":"1996","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2024.117205_bib134","doi-asserted-by":"crossref","first-page":"7463","DOI":"10.1021\/jm900756t","article-title":"Synthesis and in vitro opioid receptor functional antagonism of methyl-substituted analogues of (3R)-7-Hydroxy-N-[(1S)-1-{[(3R,4R)-4-(3-Hydroxyphenyl)-3,4-Dimethyl-1-Piperidinyl]Methyl}-2-Methylpropyl]-1,2,3,4-Tetrahydro-3-Isoquinolinecarboxamide (JDTic)","volume":"52","author":"Cueva","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117205_bib135","series-title":"Drug Discovery for Psychiatric Disorders","first-page":"1","article-title":"Psychiatric disorders \u2013 an overview","author":"Connor","year":"2012"},{"key":"10.1016\/j.ejmech.2024.117205_bib136","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1021\/jm2006035","article-title":"Design and discovery of a selective small molecule \u03ba opioid antagonist (2-methyl-N-((2\u2019-(Pyrrolidin-1-Ylsulfonyl)Biphenyl-4-Yl)Methyl)Propan-1-Amine, PF-4455242)","volume":"54","author":"Verhoest","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117205_bib137","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1124\/jpet.111.185108","article-title":"Pharmacological characterization of 2-methyl-N-((2\u2019-(Pyrrolidin-1-Ylsulfonyl)Biphenyl-4-Yl)Methyl)Propan-1-Amine (PF-04455242), a high-affinity antagonist selective for \u03ba-opioid receptors","volume":"339","author":"Grimwood","year":"2011","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2024.117205_bib138","doi-asserted-by":"crossref","first-page":"8000","DOI":"10.1021\/jm200789r","article-title":"Discovery of aminobenzyloxyarylamides as \u03ba opioid receptor selective antagonists: application to preclinical development of a \u03ba opioid receptor antagonist receptor occupancy tracer","volume":"54","author":"Mitch","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117205_bib139","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.neuropharm.2013.09.021","article-title":"LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders","volume":"77","author":"Rorick-Kehn","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2024.117205_bib140","doi-asserted-by":"crossref","DOI":"10.1038\/s41386-024-01862-x","article-title":"Efficacy and safety of aticaprant, a kappa receptor antagonist, adjunctive to oral SSRI\/SNRI antidepressant in major depressive disorder: results of a phase 2 randomized, double-blind, placebo-controlled study","author":"Schmidt","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejmech.2024.117205_bib141","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1038\/s41386-018-0015-y","article-title":"Preclinical evaluation of the kappa-opioid receptor antagonist CERC-501 as a candidate therapeutic for alcohol use disorders","volume":"43","author":"Domi","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejmech.2024.117205_bib142","doi-asserted-by":"crossref","DOI":"10.1111\/adb.12799","article-title":"A randomized, double-blind, placebo-controlled study of the kappa opioid receptor antagonist, CERC-501, in a human laboratory model of smoking behavior","volume":"25","author":"Jones","year":"2020","journal-title":"Addiction Biol."},{"key":"10.1016\/j.ejmech.2024.117205_bib143","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/jhet.4580","article-title":"Efficient preparation of (S)\u20102\u2010(3,5\u2010dimethylphenyl)Pyrrolidine via a recycle process of resolution","volume":"60","author":"Duan","year":"2023","journal-title":"J. Heterocycl. Chem."},{"key":"10.1016\/j.ejmech.2024.117205_bib144","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1021\/acs.jmedchem.8b01679","article-title":"Design and synthesis of a novel and selective kappa opioid receptor (KOR) antagonist (BTRX-335140)","volume":"62","author":"Guerrero","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117205_bib145","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/s41386-022-01485-0","article-title":"ACNP 61st annual meeting: poster abstracts P271-P540","volume":"47","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejmech.2024.117205_bib146","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2147\/NDT.S199245","article-title":"Buprenorphine\/samidorphan combination for the adjunctive treatment of major depressive disorder: results of a phase III clinical trial (FORWARD-3)","volume":"15","author":"Zajecka","year":"2019","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.ejmech.2024.117205_bib147","doi-asserted-by":"crossref","first-page":"18396","DOI":"10.1073\/pnas.0910180106","article-title":"Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action","volume":"106","author":"Aldrich","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2024.117205_bib148","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1399-3011.2005.00216.x","article-title":"Structure-activity relationships of arodyn, a novel acetylated kappa opioid receptor antagonist","volume":"65","author":"Bennett","year":"2005","journal-title":"J. Pept. Res."},{"key":"10.1016\/j.ejmech.2024.117205_bib149","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.bmc.2017.11.029","article-title":"Design, synthesis, and opioid activity of arodyn analogs cyclized by ring-closing metathesis involving Tyr(allyl)","volume":"26","author":"Fang","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117205_bib150","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/164_2021_519","article-title":"Peptide kappa opioid receptor ligands and their potential for drug development","volume":"271","author":"Aldrich","year":"2022","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.117205_bib151","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.neulet.2016.01.017","article-title":"Two short-acting kappa opioid receptor antagonists (zyklophin and LY2444296) exhibited different behavioral effects from the long-acting antagonist norbinaltorphimine in mouse anxiety tests","volume":"615","author":"Huang","year":"2016","journal-title":"Neurosci. Lett."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424010870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424010870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T05:59:38Z","timestamp":1759298378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424010870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":151,"alternative-id":["S0223523424010870"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117205","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review of kappa opioid receptor antagonists and their clinical trial landscape","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117205","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117205"}}